A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease
Study sponsor: Spero Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-10-08Actual
Enrollment · participants25Actual
Source updated2025-10-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.